A Multi-Centered Case Series Highlighting the Clinical Use and Dosing of Lidocaine and Mexiletine for Refractory Cancer Pain

References

• Collinsworth KA, Kalman SM, Harrison DC. The clinical pharmacology of lidocaine as an antiarrhythymic drug. Circulation. 1974;50(6):1217–30. doi:10.1161/01.CIR.50.6.1217.
   PubMed Web of Science ®Google Scholar
• Manolis AS, Deering TF, Cameron J, Estes NA, 3rd. Mexiletine: pharmacology and therapeutic use. Clin Cardiol. 1990;13(5):349–59. doi:10.1002/clc.4960130509.
   PubMed Web of Science ®Google Scholar
• Nguyen NL, Kome AM, Lowe DK, Coyne P, Hawks KG. Intravenous lidocaine as an adjuvant for pain associated with sickle cell disease. J Pain Palliat Care Pharmacother. 2015;29(4):359–64. doi:10.3109/15360288.2015.1082009.
   PubMedGoogle Scholar
• Koppert W, Ostermeier N, Sittl R, Weidner C, Schmelz M. Low-dose lidocaine reduces secondary hyperalgesia by a central mode of action. Pain. 2000;85(1):217–24. doi:10.1016/S0304-3959(99)00268-7.
   PubMed Web of Science ®Google Scholar
• Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D. Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology. 2004;62(2):218–25. doi:10.1212/01.WNL.0000103237.62009.77.
   PubMed Web of Science ®Google Scholar
• Baranowski AP, De Courcey J, Bonello E. A trial of intravenous lidocaine on the pain and allodynia of postherpetic neuralgia. J Pain Symptom Manage. 1999;17(6):429–33. doi:10.1016/S0885-3924(99)00032-9.
   PubMed Web of Science ®Google Scholar
• Peixoto RD, Hawley P. Intravenous lidocaine for cancer pain without electrocardiographic monitoring: a retrospective review. J Palliat Med. 2015;18(4):373–7. doi:10.1089/jpm.2014.0279.
   PubMed Web of Science ®Google Scholar
• Kastrup J, Angelo H, Petersen P, et al. Treatment of chronic painful diabetic neuropathy with intravenous lidocaine infusion. Br Med J. 1986;292(6514):173–3. doi:10.1136/bmj.292.6514.173.
   PubMedGoogle Scholar
• Posner IA. Treatment of fibromyalgia syndrome with intravenous lidocaine. J Musculoskelet Pain. 1994;2(4):55–65. doi:10.1300/J094v02n04_05.
   Google Scholar
• Groudine SB, Fisher HA, Kaufman RP, Jr, Patel MK, Wilkins LJ, Mehta SA, Lumb PD. Intravenous lidocaine speeds the return of bowel function, decreases postoperative pain, and shortens hospital stay in patients undergoing radical retropubic prostatectomy. Anesth Analg. 1998;86(2):235–9. doi:10.1097/00000539-199802000-00003.
   PubMed Web of Science ®Google Scholar
• Chabal C, Jacobson L, Mariano A, Chaney E, Britell CW. The use of oral mexiletine for the treatment of pain after peripheral nerve injury. Anesthesiology. 1992;76(4):513–17. doi:10.1097/00000542-199204000-00005.
   PubMed Web of Science ®Google Scholar
• Chiou-Tan FY, Tuel SM, Johnson JC, Priebe MM, Hirsh DD, Strayer JR. Effect of mexiletine on spinal cord injury dysesthetic pain. Am J Phys Med Rehabil. 1996;75(2):84–7. doi:10.1097/00002060-199603000-00002.
   PubMed Web of Science ®Google Scholar
• Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care. 1997;20(10):1594–7. doi:10.2337/diacare.20.10.1594.
   PubMed Web of Science ®Google Scholar
• Stracke H, Meyer U, Schumacher H, Armbrecht U, Beroniade S, Buch KD, Federlin K, Haupt E, Husstedt IW, Kampmann B, et al. [Mexiletine in treatment of painful diabetic neuropathy]. Med Klin (Munich). 1994;89(3):124–31.
   PubMedGoogle Scholar
• Stracke H, Meyer UE, Schumacher HE, Federlin K. Mexiletine in the treatment of diabetic neuropathy. Diabetes Care. 1992;15(11):1550–55. doi:10.2337/diacare.15.11.1550.
   PubMed Web of Science ®Google Scholar
• Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000;28(8):959–5.
   PubMed Web of Science ®Google Scholar
• Labbe L, Turgeon J. Clinical pharmacokinetics of mexiletine. Clin Pharmacokinet. 1999;37(5):361–84. doi:10.2165/00003088-199937050-00002.
   PubMed Web of Science ®Google Scholar
• Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. J Pain Symptom Manage. 1996;12(3):161–7. doi:10.1016/0885-3924(96)00126-1.
   PubMed Web of Science ®Google Scholar
• Tremont-Lukats IW, Challapalli V, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2005;101(6):1738–49. doi:10.1213/01.ANE.0000186348.86792.38.
   PubMed Web of Science ®Google Scholar
• Wu CL, Tella P, Staats PS, Vaslav R, Kazim DA, Wesselmann U, Raja SN. Analgesic effects of intravenous lidocaine and morphine on postamputation pain: a randomized double-blind, active placebo-controlled, crossover trial. Anesthesiology. 2002;96(4):841–8. doi:10.1097/00000542-200204000-00010.
   PubMed Web of Science ®Google Scholar
• Gowda S, Desai PB, Hull VV, Math AA, Vernekar SN, Kulkarni SS. A review on laboratory liver function tests. Pan Afr Med J. 2009;3:17.
   PubMedGoogle Scholar
• Robert A, Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology. 1996;24(6):1392–4. doi:10.1002/hep.510240613.
   PubMed Web of Science ®Google Scholar
• Savelloni J, Gunter H, Lee KC, Hsu C, Yi C, Edmonds KP, Furnish T, Atayee RS. Risk of respiratory depression with opioids and concomitant gabapentinoids. J Pain Res. 2017;10:2635–41. doi:10.2147/JPR.S144963.
   PubMed Web of Science ®Google Scholar
• Walker PW, Palla S, Pei BL, Kaur G, Zhang K, Hanohano J, Munsell M, Bruera E. Switching from methadone to a different opioid: what is the equianalgesic dose ratio? J Palliat Med. 2008;11(8):1103–8. doi:10.1089/jpm.2007.0285.
   PubMed Web of Science ®Google Scholar
• Christie JM, Valdes C, Markowsky SJ. Neurotoxicity of lidocaine combined with mexiletine. Anesth Analg. 1993;77(6):1291–4.
   PubMed Web of Science ®Google Scholar
• Denaro CP, Benowitz NL. Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide. Med Toxicol Adverse Drug Exp. 1989;4(6):412–28. doi:10.1007/BF03259923.
   PubMedGoogle Scholar
• Campbell TJ, Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol. 1998;46(4):307–19. doi:10.1046/j.1365-2125.1998.t01-1-00768.x.
   PubMed Web of Science ®Google Scholar
• Kandil E, Melikman E, Adinoff B. Lidocaine infusion: a promising therapeutic approach for chronic pain. J Anesth Clin Res. 2017;08(01). doi:10.4172/2155-6148.1000697.
   Google Scholar
• Clinical Pharmacology. [accessed 2019 Jul 6]. https://clinicalpharmacology-ip.com/default.aspx.
   Google Scholar